Perspective Therapeutics, Inc. (CATX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 4M 8M 12M Q3 '21: 10.2M Q4 '21: 10.7M Q1 '22: 8.1M Q2 '22: 5.4M Q3 '22: 2.8M Q4 '22: 0 Q1 '23: 233K Q2 '23: 821K Q3 '23: 1.1M Q4 '23: 1.4M Q1 '24: 1.5M Q2 '24: 1.5M Q3 '24: 1.6M Q4 '24: 1.5M Q1 '25: 1.5M Q2 '25: 1.2M Q3 '25: 1.1M Q4 '25: 884K Q1 '26: 618K Q2 '26: 409K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 2M 4M 6M Q1 '19: 2.6M Q2 '19: 3M Q3 '19: 3.8M Q4 '19: 4.1M Q1 '20: 4.9M Q2 '20: 5.1M Q3 '20: 5.1M Q4 '20: 5.2M Q1 '21: 4.8M Q2 '21: 5.1M Q3 '21: 4.9M Q4 '21: 5M Q1 '22: 5M Q2 '22: 4.6M Q3 '22: 4M Q4 '22: 2.4M Q1 '23: 1.4M Q2 '23: 735K Q3 '23: 1.1M Q4 '23: 1.4M Q2 '19 Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23

Operating Income TTM

-150M -100M -50M 0 50M 100M 150M Q3 '21: -5M Q4 '21: -5.8M Q1 '22: -6.4M Q2 '22: -7.4M Q3 '22: -9.3M Q4 '22: -9.1M Q1 '23: -17.5M Q2 '23: -25.1M Q3 '23: -30.7M Q4 '23: -40.9M Q1 '24: -44.2M Q2 '24: -48.7M Q3 '24: -57.6M Q4 '24: -90.9M Q1 '25: -99.7M Q2 '25: -109.5M Q3 '25: -118.7M Q4 '25: -113.6M Q1 '26: -120M Q2 '26: -125.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-120M -80M -40M 0 40M 80M 120M Q3 '21: -4.9M Q4 '21: -5.7M Q1 '22: -6.3M Q2 '22: -7.3M Q3 '22: -9.1M Q4 '22: -10.8M Q1 '23: -9.8M Q2 '23: -18.8M Q3 '23: -25.1M Q4 '23: -46.5M Q1 '24: -58.4M Q2 '24: -59M Q3 '24: -63.8M Q4 '24: -79.3M Q1 '25: -85.2M Q2 '25: -95M Q3 '25: -105.8M Q4 '25: -103.1M Q1 '26: -111.1M Q2 '26: -116.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 2.5M 5M 7.5M Q4 '18: 4.3M Q1 '19: 4.4M Q2 '19: 4.3M Q3 '19: 4.3M Q4 '19: 4.3M Q1 '20: 4.4M Q2 '20: 4.6M Q3 '20: 4.6M Q4 '20: 4.7M Q1 '21: 4.8M Q2 '21: 4.9M Q3 '21: 5.3M Q4 '21: 5.7M Q1 '22: 6M Q2 '22: 6.2M Q3 '22: 5.9M Q4 '22: 5.8M Q1 '23: 5.9M Q2 '23: 6.2M Q3 '23: 6.3M Q1 '19 Q4 '19 Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23

Operating Cash Flow TTM

-105M -70M -35M 0 35M 70M 105M Q3 '21: -4.6M Q4 '21: -5.1M Q1 '22: -5.9M Q2 '22: -7.7M Q3 '22: -7.4M Q4 '22: -10.4M Q1 '23: -18.7M Q2 '23: -23.9M Q3 '23: -32.2M Q4 '23: -36.9M Q1 '24: -13.3M Q2 '24: -14.2M Q3 '24: -696K Q4 '24: -18.3M Q1 '25: -53.7M Q2 '25: -64.8M Q3 '25: -84.4M Q4 '25: -82.5M Q1 '26: -92.4M Q2 '26: -93.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-150M -100M -50M 0 50M 100M 150M Q3 '21: -4.9M Q4 '21: -5.5M Q1 '22: -6.2M Q2 '22: -8M Q3 '22: -7.7M Q4 '22: -10.7M Q1 '23: -19.2M Q2 '23: -24.8M Q3 '23: -33.3M Q4 '23: -38M Q1 '24: -23.3M Q2 '24: -24.6M Q3 '24: -40.6M Q4 '24: -72.7M Q1 '25: -103.7M Q2 '25: -114.8M Q3 '25: -106.7M Q4 '25: -95.2M Q1 '26: -107.3M Q2 '26: -121.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 80M 160M 240M Q3 '20: 68.9M Q4 '20: 83M Q1 '21: 122.6M Q2 '21: 141.7M Q3 '21: 141.9M Q4 '21: 142M Q1 '22: 142M Q2 '22: 142M Q3 '22: 142.1M Q1 '23: 228.6M Q2 '23: 28M Q3 '23: 28.1M Q1 '24: 49.5M Q2 '24: 66.6M Q3 '24: 70.6M Q1 '25: 72.4M Q2 '25: 74.2M Q3 '25: 74.3M Q1 '26: 103.6M Q2 '26: 120.7M Q4 '20 Q3 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.10 -1.40 -0.70 0.00 0.70 1.40 2.10 Q3 '21: -0.05 Q4 '21: -0.05 Q1 '22: -0.05 Q2 '22: -0.05 Q3 '22: -0.06 Q4 '22: -0.07 Q1 '23: -0.06 Q2 '23: -0.45 Q3 '23: -0.79 Q4 '23: -1.68 Q1 '24: -1.93 Q2 '24: -1.71 Q3 '24: -1.55 Q4 '24: -1.25 Q1 '25: -1.25 Q2 '25: -1.36 Q3 '25: -1.50 Q4 '25: -1.40 Q1 '26: -1.40 Q2 '26: -1.33 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.